RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address high unmet medical needs. We believe that we are well positioned to compete successfully using our RNAi technology platform for the development of novel therapeutics to improve patients’ lives. The Company is supported by a proven and experienced management team, an accomplished Scientific Advisory Board and an extensive intellectual property portfolio.
PROPRIETARY SELF-DELIVERING RNAi (sd-rxRNA®) TECHNOLOGY PLATFORM
Provided by Nasdaq.
Oct 18, 2017 at 2:45 PM PDT2017 Annual BIO Investor Forum
Sep 26, 2017 at 11:30 AM EDTLadenburg Thalmann Healthcare Conference
Sep 26, 2017 at 10:45 AM EDTBioPharm America’s 10th Annual International Partnering Conference